Ocala

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)4 trials
• Liver cirrhosis2 trials
• COPD1 trial
• Irritable bowel syndrome1 trial
• Lung cancer1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Recruiting6 trials
• Active, not recruiting1 trial

Lead sponsor

• GlaxoSmithKline7 trials

Running trials

• Recruiting

  A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07701993· Phase 3· GlaxoSmithKline· Source

  Contact: Robert Barish (principal investigator)

• Recruiting

  A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07704892· Phase 3· GlaxoSmithKline· Source

  Contact: Robert Barish (principal investigator)

• Recruiting

  A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

  NCT07519395· Phase 2· GlaxoSmithKline· Source

  Contact: Robert Barish (principal investigator)

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

  Contact: Robert Barish (principal investigator)

• Recruiting

  A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

  NCT07221227· Phase 3· GlaxoSmithKline· Source

  Contact: Robert Barish (principal investigator)

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  NCT06961214· Phase 3· GlaxoSmithKline· Source

  Contact: Raj Karunakara (principal investigator)

• Active, not recruiting

  A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

  NCT06472076· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)4 recruiting
• Liver cirrhosis2 recruiting
• COPD1 recruiting
• Irritable bowel syndrome1 recruiting